Cypress Returns Fire Against Glaxo Over Zantac

Law360, New York (July 18, 2007, 12:00 AM EDT) -- A generic drug maker has opposed Glaxo Group Ltd.'s patent claims over ulcer drug Zantac, claiming that the patent is invalid and noninfringed.

Cypress Pharmaceutical Inc. filed counterclaims against Glaxo in the U.S. District Court for the Southern District of New York on Tuesday, saying that its Abbreviated New Drug Application for a generic Zantac syrup does not infringe any valid claims for Glaxo's patent, U.S. Patent Number 5,068,249.

“Cypress' commercial manufacture, use, sale or offer to sell Cypress' product for which it seeks FDA approval...
To view the full article, register now.